Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aristolochic acid I is a **naturally occurring nitrophenanthrene carboxylic acid** and the most abundant member of the aristolochic acids found in herbs of the Aristolochiaceae family, such as Aristolochia and Asarum[1][4]. It is a **highly carcinogenic, mutagenic, and nephrotoxic phytochemical**, historically present in herbal remedies, especially traditional Chinese medicine[1]. AA-I is absorbed orally, distributed systemically, and primarily metabolized by phase I nitroreduction to aristolactam I, which forms **stable DNA adducts** leading to A→T transversion mutations and selective TP53 tumor suppressor gene mutations[1][3][5]. It acts as a **phospholipase A2 inhibitor** and is bioactivated to reactive N-acylnitrenium ions that alkylate DNA, driving its mutagenic and carcinogenic effects[3][5]. AA-I has been definitively linked to urothelial malignancy, kidney failure, and aristolochic acid nephropathy (AAN)[1][5]. It is not approved for any pharmaceutical indication and is considered a toxin, not a therapeutic drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aristolochic acid I.